Top

Published in:

01-03-2018 | Review and Perspectives

Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms

Authors: Günter Klöppel, Stefano La Rosa

Published in: Virchows Archiv | Issue 3/2018

Abstract

In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where the antibody was produced in the university department of pathology and refers to the number of the original clone (67). Systematic assessment of the proliferative activity of tumors using Ki67 started in the 1990s, when Ki67, which only worked on frozen tissue, was complemented by the antibody MIB-1 that also worked in formalin-fixed tissues. Pancreatic neuroendocrine neoplasms (PanNENs) were the first endocrine tumors whose proliferative activity was assessed with Ki67. This approach was so successful that Ki67 was included as prognostic marker in the 2000 and 2004 WHO classifications of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In 2010, the WHO classification of GEP-NENs introduced a three-tiered grading, originally proposed by ENETS in 2006 that was mainly based on the Ki67 index. As it has subsequently been shown that the Ki67 index is the most reliable factor in the prognostic evaluation of GEP-NENs, especially of PanNENs, the 2017 WHO classification of PanNENs requires its use and strongly recommends exact assessment of the proportion Ki67-labeled cells as basis for the calculation of the Ki67 index. Problems in assessing the Ki67 index include intertumoral and intratumoral staining heterogeneity and counting methods. Despite such problems, the Ki67 index has emerged as indispensable for the prognostic and therapeutic stratification of the majority of GEP-NENs and can barely be replaced by counting mitoses. In future, however, it can be anticipated that the Ki67 cut-offs experience refinement in relation to the type of tumor, its location, and its response to therapy. It is also possible that the prognostic risk of an individual tumor is calculated for each Ki67 unit and not for an “a priori” fixed Ki67 class.

Adsay V (2012) Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am J Surg Pathol 36:1743–1746. https://doi.org/10.1097/PAS.0b013e318272ff77 CrossRefPubMed

Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885–894. https://doi.org/10.1677/erc-09-0042 CrossRefPubMed

Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S (2013) Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PloS one 8:e61538. https://doi.org/10.1371/journal.pone.0061538 CrossRefPubMedPubMedCentral

Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS (2015) The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39:683–690. https://doi.org/10.1097/PAS.0000000000000408 CrossRefPubMedPubMedCentral

Blank A, Wehweck L, Marinoni I, Boos LA, Bergmann F, Schmitt AM, Perren A (2015) Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors. Virchows Arch 467:543–550. https://doi.org/10.1007/s00428-015-1843-3 CrossRefPubMed

Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425:547–560CrossRefPubMed

Clift AK, Faiz O, Al-Nahhas A, Bockisch A, Liedke MO, Schloericke E, Wasan H, Martin J, Ziprin P, Moorthy K, Frilling A (2016) Role of staging in patients with small intestinal neuroendocrine tumours. J Gastrointest Surg 20:180–188; discussion 188. https://doi.org/10.1007/s11605-015-2953-6 CrossRefPubMed

Clift AK, Faiz O, Goldin R, Martin J, Wasan H, Liedke MO, Schloericke E, Malczewska A, Rindi G, Kidd M, Modlin IM, Frilling A (2017) Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocr Connect 6:71–81. https://doi.org/10.1530/ec-16-0114 CrossRefPubMedPubMedCentral

Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL (2016) Loss of antigenicity with tissue age in breast cancer. Lab Invest 96:264–269. https://doi.org/10.1038/labinvest.2015.138 CrossRefPubMed

10.

Cunningham JL, Grimelius L, Sundin A, Agarwal S, Janson ET (2007) Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol 46:747–756. https://doi.org/10.1080/02841860701218659 CrossRefPubMed

11.

Cuylen S, Blaukopf C, Politi AZ, Muller-Reichert T, Neumann B, Poser I, Ellenberg J, Hyman AA, Gerlich DW (2016) Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature 535:308–312. https://doi.org/10.1038/nature18610 CrossRefPubMedPubMedCentral

12.

Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13–20CrossRefPubMed

13.

Gonzalez RS, Liu EH, Alvarez JR, Ayers GD, Washington MK, Shi C (2014) Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? Mod Pathol 27:1288–1295. https://doi.org/10.1038/modpathol.2013.232 CrossRefPubMedPubMedCentral

14.

Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ (2013) Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol 19:8687–8695. https://doi.org/10.3748/wjg.v19.i46.8687 CrossRefPubMedPubMedCentral

15.

Hong SM, Kim YS, Moon JS, Kim JN, Oh MK, Kwon SO, Jeong SY, Hong SW, Kang YK (2013) Prognostic significance of Ki-67 expression in rectal carcinoid tumors. Korean J Gastroenterol 61:82–87CrossRefPubMed

16.

Jernman J, Valimaki MJ, Louhimo J, Haglund C, Arola J (2012) The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology 95:317–324. https://doi.org/10.1159/000333035 CrossRefPubMed

17.

Kim GU, Kim KJ, Hong SM, Yu ES, Yang DH, Jung KW, Ye BD, Byeon JS, Myung SJ, Yang SK, Kim JH (2013) Clinical outcomes of rectal neuroendocrine tumors≤ 10 mm following endoscopic resection. Endoscopy 45:1018–1023. https://doi.org/10.1055/s-0033-1344860 CrossRefPubMed

18.

Klöppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–16. https://doi.org/10.1530/erc-11-0013 CrossRefPubMed

19.

Klöppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann NY Acad Sci 1014:13–27CrossRefPubMed

20.

Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, Agaimy A, Sipos B, Zamboni G, Weichert W, Esposito I, Pfarr N, Klöppel G (2017) Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol. https://doi.org/10.1038/modpathol.2016.217

21.

Kreipe H, Heidebrecht HJ, Hansen S, Rohlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ, Parwaresch R (1993) A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 142:3–9PubMedPubMedCentral

22.

La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E (2011) Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 42:1373–1384. https://doi.org/10.1016/j.humpath.2011.01.018 CrossRefPubMed

23.

La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E (1996) Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429:323–333CrossRefPubMed

24.

La Rosa S, Sessa F, Uccella S (2016) Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol 27:284–311. https://doi.org/10.1007/s12022-016-9432-9 CrossRefPubMed

25.

La Rosa S, Vanoli A (2014) Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol 67:938–948. https://doi.org/10.1136/jclinpath-2014-202515 CrossRefPubMed

26.

Lardiere-Deguelte S, de Mestier L, Appere F, Vullierme MP, Zappa M, Hoeffel C, Noaves M, Brixi H, Hentic O, Ruszniewski P, Cadiot G, Panis Y, Kianmanesh R (2016) Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery. Neuroendocrinology 103:552–559. https://doi.org/10.1159/000441423 CrossRefPubMed

27.

Li P, Wu F, Zhao H, Dou L, Wang Y, Guo C, Wang G, Zhao D (2015) Analysis of the factors affecting lymph node metastasis and the prognosis of rectal neuroendocrine tumors. Int J Clin Exp Pathol 8:13331–13338PubMedPubMedCentral

28.

Lloyd RV, Osamura RY, Klöppel G, Rosai J (2017) WHO Classification of Tumours of Endocrine Organs. IARC Press, Lyon

29.

Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L, Pisa E, Barberis M, Vanoli A, Buzzoni R, Pusceddu S, Concas L, Sessa F, Solcia E, Capella C, Fazio N, La Rosa S (2017) The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104:85–93. https://doi.org/10.1159/000445165 CrossRefPubMed

30.

Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B, Kidd M (2010) A nomogram to assess small-intestinal neuroendocrine tumor (‘carcinoid’) survival. Neuroendocrinology 92:143–157. https://doi.org/10.1159/000319784 CrossRefPubMed

31.

Nakamura K, Osada M, Goto A, Iwasa T, Takahashi S, Takizawa N, Akahoshi K, Ochiai T, Nakamura N, Akiho H, Itaba S, Harada N, Iju M, Tanaka M, Kubo H, Somada S, Ihara E, Oda Y, Ito T, Takayanagi R (2016) Short- and long-term outcomes of endoscopic resection of rectal neuroendocrine tumours: analyses according to the WHO 2010 classification. Scand J Gastroenterol 51:448–455. https://doi.org/10.3109/00365521.2015.1107752 CrossRefPubMed

32.

Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, Janson ET, Hellman P, Akerstrom G (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36:1419–1431. https://doi.org/10.1007/s00268-011-1296-z CrossRefPubMed

33.

O’Toole D, Kianmanesh R, Caplin M (2016) ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology 103:117–118. https://doi.org/10.1159/000443169 CrossRefPubMed

34.

Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29:2372–2377. https://doi.org/10.1200/jco.2010.33.0688 CrossRefPubMed

35.

Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M (2012) Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors. Neuroendocrinology 96:32–40. https://doi.org/10.1159/000334038 CrossRefPubMed

36.

Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Röcken C, Rindi G, Wiedenmann B (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265CrossRefPubMed

37.

Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Oberg K, Pavel M, Perren A, Toumpanakis C, O’Connor J, Krenning E, Reed N, O’Toole D (2016) ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 103:144–152. https://doi.org/10.1159/000443165 CrossRefPubMed

38.

Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, Zamboni G (1996) Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 27:1124–1134CrossRefPubMed

39.

Pelosi G, Rindi G, Travis WD, Papotti M (2014) Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 9:273–284. https://doi.org/10.1097/jto.0000000000000092 CrossRefPubMed

40.

Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, Ruszniewski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A (2016) ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology 103:139–143. https://doi.org/10.1159/000443166 CrossRefPubMed

41.

Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, Balci S, Gucer H, Jang KT, Tajiri T, Basturk O, Kong SY, Goodman M, Akkas G, Adsay V (2015) Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol 28:686–694. https://doi.org/10.1038/modpathol.2014.156 CrossRefPubMed

42.

Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532–542CrossRefPubMed

43.

Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Kloppel G et al. (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO Classification of Tumours of the Digestive system, 4th edn. IARC, Lyon, pp 13–14

44.

Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, La Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104:764–777. https://doi.org/10.1093/jnci/djs208 CrossRefPubMed

45.

Rindi G, Klöppel G, Ahlman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, participants aaoFCC (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401CrossRefPubMedPubMedCentral

46.

Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762CrossRefPubMed

47.

Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104:994–1006CrossRefPubMed

48.

Rosentraeger MJ, Garbrecht N, Anlauf M, Raffel A, Knoefel WT, Wiedenmann B, Klöppel G (2016) Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch 468:277–287. https://doi.org/10.1007/s00428-015-1890-9

49.

Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R, Coindre JM (1997) Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study. Am J Pathol 150:1997–2007PubMedPubMedCentral

50.

Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23:824–833. https://doi.org/10.1038/modpathol.2010.58 CrossRefPubMed

51.

Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G (2011) Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 3:133–139. https://doi.org/10.4253/wjge.v3.i7.133

52.

Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Lleres D, Gerbe F, Prieto S, Krasinska L, David A, Eguren M, Birling MC, Urbach S, Hem S, Dejardin J, Malumbres M, Jay P, Dulic V, Lafontaine D, Feil R, Fisher D (2016) The cell proliferation antigen Ki-67 organises heterochromatin. eLife 5:e13722. https://doi.org/10.7554/eLife.13722 CrossRefPubMedPubMedCentral

53.

Sohn JH, Cho MY, Park Y, Kim H, Kim WH, Kim JM, Jung ES, Kim KM, Lee JH, Chan HK, Park DY, Joo M, Kim S, Moon WS, Kang MS, Jin SY, Kang YK, Yoon SO, Han H, Choi E (2015) Prognostic significance of defining L-cell type on the biologic behavior of rectal neuroendocrine tumors in relation with pathological parameters. Cancer Res Treat 47:813–822. https://doi.org/10.4143/crt.2014.238 CrossRefPubMedPubMedCentral

54.

Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK (2013) Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 31:420–425. https://doi.org/10.1200/jco.2012.44.5924 CrossRefPubMed

55.

Sugimoto S, Hotta K, Shimoda T, Imai K, Yamaguchi Y, Nakajima T, Oishi T, Mori K, Takizawa K, Kakushima N, Tanaka M, Kawata N, Matsubayashi H, Ono H (2016) The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors. Surg Endosc 30:4239–4248. https://doi.org/10.1007/s00464-015-4735-3 CrossRefPubMed

56.

Tang LH, Basturk O, Sue JJ, Klimstra DS (2016) A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 40:1192–1202. https://doi.org/10.1097/pas.0000000000000662 CrossRefPubMedPubMedCentral

57.

Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 36:1761–1770. https://doi.org/10.1097/PAS.0b013e318263207c CrossRefPubMed

58.

Tsukamoto S, Fujita S, Yamaguchi T, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T (2008) Clinicopathological characteristics and prognosis of rectal well-differentiated neuroendocrine tumors. Int J Color Dis 23:1109–1113. https://doi.org/10.1007/s00384-008-0505-1 CrossRef

59.

Vanoli A, La Rosa S, Klersy C, Grillo F, Albarello L, Inzani F, Maragliano R, Manca R, Luinetti O, Milione M, Doglioni C, Rindi G, Capella C, Solcia E (2017) Four neuroendocrine tumor types and neuroendocrine carcinoma of the duodenum: analysis of 203 cases. Neuroendocrinology 104:112–125. https://doi.org/10.1159/000444803 CrossRefPubMed

60.

Vinik AI, Woltering EA, Warner RR, Caplin M, O’Dorisio TM, Wiseman GA, Coppola D, Go VL (2010) NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39:713–734. https://doi.org/10.1097/MPA.0b013e3181ebaffd CrossRefPubMed

61.

Volante M, Daniele L, Asioli S, Cassoni P, Comino A, Coverlizza S, De Giuli P, Fava C, Manini C, Berruti A, Papotti M (2013) Tumor staging but not grading is associated with adverse clinical outcome in neuroendocrine tumors of the appendix: a retrospective clinical pathologic analysis of 138 cases. Am J Surg Pathol 37:606–612. https://doi.org/10.1097/PAS.0b013e318275d1d7 CrossRefPubMed

62.

von Herbay A, Sieg B, Schurmann G, Hofmann WJ, Betzler M, Otto HF (1991) Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut 32:949–953CrossRef

63.

Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173–184. https://doi.org/10.1097/PAS.0b013e3182417d36 CrossRefPubMedPubMedCentral

64.

Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35:853–860. https://doi.org/10.1097/PAS.0b013e31821a0696 CrossRefPubMed

Title: Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms
Authors: Günter Klöppel
Stefano La Rosa
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 3/2018
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-017-2258-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Metastatic malignant PEComa of the leg with identification of ATRX mutation by next-generation sequencing

Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics

World Health Organization 4th edition of head and neck tumor classification: insight into the consequential modifications

Paratesticular alveolar rhabdomyosarcomas do not harbor typical translocations: a distinct entity with favorable prognosis?

Placental pathology varies in hypertensive conditions of pregnancy

Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer